Editors' ChoiceMEDICINE

Papers of note in Science Translational Medicine 9 (393)

See allHide authors and affiliations

Science Signaling  13 Jun 2017:
Vol. 10, Issue 483, eaao0286
DOI: 10.1126/scisignal.aao0286

This week’s articles describe a new combination therapy for BRCA1-mutant breast cancer and a new therapeutic target in patients with the ectopic calcification disease PXE.


Bringing out the neoantigens

Nolan et al. show that a two-hit combination therapy—first increasing mutational load with cisplatin, then blocking tumor- or exhaustion-mediated suppression of infiltrating immune cells—may slow the growth of BRCA1-mutant breast cancers.


The ABCs of PXE

Ziegler et al. reveal that inhibiting the alkaline phosphatase TNAP, thereby functionally relieving a calcification inhibitor, might be therapeutic for patients with pseudoxanthoma elasticum (PXE).

Highlighted Articles

Stay Connected to Science Signaling

Navigate This Article